Status:
COMPLETED
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Janssen Scientific Affairs, LLC
Conditions:
Schizophrenia
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia...
Detailed Description
Schizophrenia is a chronic, severe, and disabling brain disorder. People with schizophrenia often experience hallucinations, delusions, thought disorders, and movement disorders. These symptoms make i...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia, schizoaffective disorder (depressed type), or schizophreniform disorder
- First major episode of psychotic symptoms occurred within 2 years prior to study entry
Exclusion
- Neurological disorder or injury (e.g., encephalitis, epilepsy, traumatic brain injury)
- Mental retardation (e.g., premorbid intelligence quotient (IQ) less than 70)
- Significant alcohol or substance use during last 6 months
- Unable to complete research measures in English
- Any condition that may make risperidone use medically inadvisable
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00333177
Start Date
March 1 2006
End Date
January 1 2013
Last Update
March 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Semel Institute for Neuroscience and Human Behavior at UCLA
Los Angeles, California, United States, 90095